At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
Selumetinib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Selumetinib, Pemetrexed, and 2 other interventions for Non-Small Cell Lung Cancer. Completed, enrolled 62 participants across 12 sites.
Detailed Summary
The purpose of this study is to find out what effects a new drug, selumetinib, has on lung cancer when receiving standard chemotherapy with pemetrexed and platinum-based chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesCanada
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartMay 2015
Primary CompletionOct 2017
Study CompletionJun 2019
TodayJul 2026
First PostedJan 13, 2015
Enrollment StartMay 26, 2015
Primary CompletionOct 31, 2017
Study CompletionJun 18, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.5 years ago
Interventions
Selumetinibdrug
Pemetrexeddrug
Cisplatindrug
Carboplatindrug